
    
      Entry into the study should occur at the time the participant completes participation in one
      of the preceding studies. Upon completion of the inclusion visit, eligible participants will
      receive either RO7234292 (RG6042) every 8 weeks (Q8W) or RO7234292 (RG6042) every 16 weeks
      (Q16W) by bolus intrathecal injection.
    
  